APT Pharmaceutical

APT Pharmaceuticals was a clinical-stage biotechnology company focused on developing inhaled therapies for orphan lung diseases. The company's lead product candidate, APT-1026 (cyclosporine inhalation solution), was evaluated in a Phase 3 clinical trial for the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Despite promising early data, the Phase 3 trial failed to meet its primary endpoint in 2011, leading to the company's eventual wind-down. APT Pharmaceuticals was backed by prominent venture capital firms, including Frazier Healthcare, Canaan Partners, and New Enterprise Associates. The company's technology aimed to deliver high concentrations of immunosuppressants directly to the lungs while minimizing systemic side effects. The company's assets and intellectual property were primarily focused on the treatment of chronic rejection in solid organ transplant patients.